無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨髄性白血病細胞分化誘導タンパク質Mcl-1:パイプライン製品の分析

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H2 2018

発行 Global Markets Direct 商品コード 409619
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.03円で換算しております。
Back to Top
骨髄性白血病細胞分化誘導タンパク質Mcl-1:パイプライン製品の分析 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H2 2018
出版日: 2018年07月10日 ページ情報: 英文 69 Pages
概要

当レポートでは、骨髄性白血病細胞分化誘導タンパク質Mcl-1を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

骨髄性白血病細胞分化誘導タンパク質Mcl-1 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 初期段階の製品

企業で開発中の製品

大学/機関で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AbbVie Inc
  • Amgen Inc.
  • AstraZeneca Plc
  • Complix NV
  • Les Laboratoires Servier SAS
  • 武田薬品工業

薬剤プロファイル

休止中のプロジェクト

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indications, H2 2018
  • Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by AbbVie Inc, H2 2018
  • Pipeline by Amgen Inc, H2 2018
  • Pipeline by AstraZeneca Plc, H2 2018
  • Pipeline by Boehringer Ingelheim GmbH, H2 2018
  • Pipeline by Circle Pharma Inc, H2 2018
  • Pipeline by Complix NV, H2 2018
  • Pipeline by InteRNA Technologies BV, H2 2018
  • Pipeline by Les Laboratoires Servier SAS, H2 2018
  • Pipeline by Warp Drive Bio Inc, H2 2018
  • Pipeline by X-Rx Inc, H2 2018
  • Dormant Products, H2 2018
  • Dormant Products, H2 2018 (Contd..1), H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
目次
Product Code: GMDHC1555TDB

Summary:

According to the recently published report 'Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H2 2018'; Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) pipeline Target constitutes close to 18 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis.

The report 'Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H2 2018' outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Report covers products from therapy areas Oncology and Infectious Disease which include indications Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (Kahler Disease), Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hematological Tumor, Malignant Mesothelioma, Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Prostate Cancer, Solid Tumor and T-Cell Lymphomas.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
  • The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Overview
    • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Amgen Inc
    • AstraZeneca Plc
    • Boehringer Ingelheim GmbH
    • Circle Pharma Inc
    • Complix NV
    • InteRNA Technologies BV
    • Les Laboratoires Servier SAS
    • Warp Drive Bio Inc
    • X-Rx Inc
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Drug Profiles
    • AMG-176 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-5991 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-118 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-1B3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins to Inhibit MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-63845 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-64315 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL-1 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL1 for Multiple Myeloma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit MCL1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit MCL1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMI-77 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Dormant Products
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2018: InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
      • Apr 09, 2018: Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
      • Dec 14, 2017: Complix receives €0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies against intracellular cancer targets
      • Aug 03, 2017: Targeting Cancers Achilles Heel To Improve Breast Cancer Treatment
      • Mar 31, 2017: Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
      • Oct 20, 2016: New compound shows promise in treating multiple human cancers
      • Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy
      • Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies
      • Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
      • Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
      • Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
      • Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent
      • Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent
      • Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
      • Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top